Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. She adds that with the analysis complete, the long term clinical durability of Feraccru (to be called Accrufer in US), its cost-efficacy and ease-of-use when compared to the standard IV iron, support discussions with potential US partners.
viewShield Therapeutics PLC
Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive of ongoing discussions
Quick facts: Shield Therapeutics PLC
Price: 131.5 GBX
LSE:STX
Market: LSE
Market Cap: £154.1 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
